OBJECTIVES: To examine whether the reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is mediated by changes in insulin resistance. METHODS: This was a secondary analysis of obese pregnant women in a randomised trial (MOP trial). Fasting plasma glucose and insulin were measured in 384 of the 400 women who participated in the MOP trial. Homeostasis model assessment of insulin resistance (HOMA-IR) was compared in the metformin and placebo groups and in those that developed preeclampsia versus those that did not develop preeclampsia. RESULTS: At 28 weeks, median HOMA-IR was significantly lower in the metformin group. Logistic regression analysis demonstrated that there was a significant contribution in the prediction of preeclampsia from maternal history of chronic hypertension and gestational weight gain, but not HOMA-IR either at randomisation (p = 0.514) or at 28 weeks (p = 0.643). CONCLUSIONS: Reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is unlikely to be due to changes in insulin resistance.
OBJECTIVES: To examine whether the reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is mediated by changes in insulin resistance. METHODS: This was a secondary analysis of obese pregnant women in a randomised trial (MOP trial). Fasting plasma glucose and insulin were measured in 384 of the 400 women who participated in the MOP trial. Homeostasis model assessment of insulin resistance (HOMA-IR) was compared in the metformin and placebo groups and in those that developed preeclampsia versus those that did not develop preeclampsia. RESULTS: At 28 weeks, median HOMA-IR was significantly lower in the metformin group. Logistic regression analysis demonstrated that there was a significant contribution in the prediction of preeclampsia from maternal history of chronic hypertension and gestational weight gain, but not HOMA-IR either at randomisation (p = 0.514) or at 28 weeks (p = 0.643). CONCLUSIONS: Reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is unlikely to be due to changes in insulin resistance.
Authors: Shivalingappa Venkatesha; Mourad Toporsian; Chun Lam; Jun-ichi Hanai; Tadanori Mammoto; Yeon M Kim; Yuval Bdolah; Kee-Hak Lim; Hai-Tao Yuan; Towia A Libermann; Isaac E Stillman; Drucilla Roberts; Patricia A D'Amore; Franklin H Epstein; Frank W Sellke; Roberto Romero; Vikas P Sukhatme; Michelle Letarte; S Ananth Karumanchi Journal: Nat Med Date: 2006-06-04 Impact factor: 53.440
Authors: Gustavo Romero-Gutiérrez; Juan Manuel Malacara; Norma Amador; César Fierro-Martínez; Luis Manuel Muñoz-Guevara; Roberto Molina-Rodríguez Journal: Am J Perinatol Date: 2004-11 Impact factor: 1.862
Authors: Carolyn Chiswick; Rebecca M Reynolds; Fiona Denison; Amanda J Drake; Shareen Forbes; David E Newby; Brian R Walker; Siobhan Quenby; Susan Wray; Andrew Weeks; Hany Lashen; Aryelly Rodriguez; Gordon Murray; Sonia Whyte; Jane E Norman Journal: Lancet Diabetes Endocrinol Date: 2015-07-09 Impact factor: 32.069
Authors: David Simmons; Roland Devlieger; Andre van Assche; Sander Galjaard; Rosa Corcoy; Juan M Adelantado; Fidelma Dunne; Gernot Desoye; Alexandra Kautzky-Willer; Peter Damm; Elisabeth R Mathiesen; Dorte M Jensen; Lise Lotte T Andersen; Annunziata Lapolla; Maria G Dalfra; Alessandra Bertolotto; Ewa Wender-Ozegowska; Agnieszka Zawiejska; David Hill; Frank J Snoek; Mireille N M van Poppel Journal: Nutrients Date: 2018-10-23 Impact factor: 5.717